Mass Medical Angels
Jeffrey Chizmas is an accomplished entrepreneur and investor with extensive experience in various industries. As the Owner and CEO of Chizmas Ventures LLC since 2010, Jeffrey focuses on angel and venture capital investments for startups and small to medium-sized companies, emphasizing emerging trends and disruptive products. In addition to leading as an Angel Investor at CrowdComfort, which enhances organizational communication through mobile technology and cloud analytics, Jeffrey is a Member of Mass Medical Angels, supporting life sciences and healthcare investments, and serves as an Affiliate Investor with North Shore InnoVentures, a nonprofit incubator for innovative startups. Jeffrey also owns North Shore Auto Group LLC and Chizmas Holding Company, with a diverse portfolio in automobile retail, real estate, and commercial lending. Previous experience includes ownership of Cider Mill Farms Company, Inc. and a Branch Manager role at IBM overseeing a substantial insurance and financial services portfolio. Jeffrey Chizmas holds a BSBA in Marketing and Finance from Boston University and an MBA from the D'Amore-McKim School of Business at Northeastern University.
This person is not in the org chart
This person is not in any teams
Mass Medical Angels
Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.